Clinical & Medical Journals

The Lancet Haematology Template

Write in a clean editor, then format for The Lancet Haematology in one click — DocuGuru applies the official Clinical & Medical Journals template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

About the The Lancet Haematology format

The Lancet Haematology is a peer-reviewed journal published by Clinical & Medical Journals, covering Lymphoma Diagnosis and Treatment, Myeloproliferative Neoplasms: Diagnosis and Treatment, Acute Myeloid Leukemia Research. Over its lifetime it has published 2,003 papers, which have received 64,071 citations.

PublisherClinical & Medical Journals
Reference styleNumbered (Vancouver)
Numbered — [1], [2] in the text
1. Smith A, Jones B, Lee C. A representative article title. The Lancet Haematology. 2023;12(3):45–58.

Formats any DOI in The Lancet Haematology style. No sign-up.

Publishes research inLymphoma Diagnosis and Treatment Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Hemoglobinopathies and Related Disorders Chronic Lymphocytic Leukemia Research
ISSN2352-3026
Citation impact (2-yr)6.18
h-index133
i10-index686
Article processing charge$6,300
Top institutions publishing hereThe University of Texas MD Anderson Cancer Center
Journal websitewww.journals.elsevier.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in The Lancet Haematology per year

33
2014
132
2015
122
2016
146
2017
122
2018
152
2019
217
2020
199
2021
207
2022
209
2023
194
2024
177
2025

Citation impact of The Lancet Haematology by publication year

1.3K
2014
6.4K
2015
7K
2016
7.4K
2017
4.2K
2018
7.8K
2019
11.9K
2020
5.8K
2021
4.9K
2022
4.6K
2023
2.2K
2024
627
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in The Lancet Haematology

Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021

Azalea Thomson, Theresa A. McHugh, Assaf P. Oron et al. · 16 Jun 2023

BACKGROUND: Previous global analyses, with known underdiagnosis and single cause per death attribution systems, provide only a small insight into the suspected high population health effect of sickle cell disease. Completed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, this study delivers a comprehensive global assessment of prevalence…

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · 9 Apr 2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing…

Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021

William M. Gardner, Christian Razo, Theresa A. McHugh et al. · 31 Jul 2023

BACKGROUND: Anaemia is a major health problem worldwide. Global estimates of anaemia burden are crucial for developing appropriate interventions to meet current international targets for disease mitigation. We describe the prevalence, years lived with disability, and trends of anaemia and its underlying causes in 204 countries and territories. METHODS: We estimated population-level distributions of haemoglobin…

The Lancet Haematology template — frequently asked questions

How do I write a paper in the The Lancet Haematology format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the The Lancet Haematology template. When you export, DocuGuru compiles the paper into the official Clinical & Medical Journals format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does The Lancet Haematology use?
The Lancet Haematology uses Numbered (Vancouver) references, shown as numbered [1], [2] markers in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: 1. Smith A, Jones B, Lee C. A representative article title. The Lancet Haematology. 2023;12(3):45–58.
Do I need to know LaTeX to submit to The Lancet Haematology?
No. DocuGuru generates the article LaTeX class and compiles the PDF for you in the background, so you get a Clinical & Medical Journals-ready The Lancet Haematology document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the The Lancet Haematology template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the The Lancet Haematology format with correct headings, figures, tables, and numbered citations.
What is The Lancet Haematology?
Clinical journal (generic ICMJE manuscript format). It is a life sciences and medicine journal, published by Clinical & Medical Journals.
Can I export a submission-ready The Lancet Haematology PDF?
Yes — DocuGuru produces a PDF built with the official The Lancet Haematology template (the article class) that is ready to submit to Clinical & Medical Journals, together with the matching LaTeX source files.
How much does the The Lancet Haematology template cost?
You can start writing in the The Lancet Haematology template for free. Exporting the final submission-ready The Lancet Haematology PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the The Lancet Haematology template